No. 16: Becton, Dickinson (medical segment)
Franklin Lakes, N.J.
2017 revenues: $8,105,000,000
Fiscal year ending: September 30, 2017
Key Personnel:
Vincent Forlenza, chairman & CEO; Thomas Polen, president; James Borzi, EVP, global operations, chief supply chain office; Alexandre Conroy, EVP & president, Europe, EMA & Americas; Roland Goette, EVP, president, EMEA; James Lim, EVP & president, greater Asia; Alberto Mas, EVP & president, life sciences; Christopher Reidy, EVP, CFO & chief administrative officer; Nabil Shabshab, EVP, strategic planning & chief marketing officer; Ellen Strahlman, EVP, R&D & CMO; Linda Tharby, EVP & chief HR officer
Description:
Like Abbott with its St. Jude Medical buy, Becton Dickinson took time to digest its meal after closing the $24 billion acquisition of C.R. Bard last December (and the related, $100 million sale of its soft tissue core needle biopsy line and Aspira product line to Merit Medical the following February). BD in March sold its minority stake in respiratory solutions joint venture Vyaire Medical to Apax Partners for $435 million and bought TVA Medical in July 2018 for an undisclosed amount, hard on the heels of that company’s FDA clearance for its EverlinQ EndoAVF hemodialysis device.